Page 69 - Read Online

Page 4 of 5 Hou et al. Hepatoma Res 2023;9:35 https://dx.doi.org/10.20517/2394-5079.2023.40

DECLARATIONS
Authors’ contributions
Made substantial contributions to the conception and design of the study and performed data analysis and
interpretation: Hou W, Zeng Q
Conception, design, and administrative support: Zheng M
Made substantial contributions to data collection, analysis and interpretation: Tu Y

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management.
Cancer Lett 2016;379:198-205. DOI PubMed
2. Li Q, Chen C, Su J, et al. Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical
resection: a multi-institutional study. BMC Cancer 2022;22:329. DOI PubMed PMC
3. Zhang XF, Chakedis J, Bagante F, et al. Implications of intrahepatic cholangiocarcinoma etiology on recurrence and prognosis after
curative-intent resection: a multi-institutional study. World J Surg 2018;42:849-57. DOI
4. Wang Q, Li J, Lei Z, et al. Prognosis of intrahepatic cholangiocarcinomas with hbv infection is better than those with hepatolithiasis
after R0 liver resection: a propensity score matching analysis. Ann Surg Oncol 2017;24:1579-87. DOI
5. Amin MB. American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. Eight edition. Chicago, IL:
American Joint Committee on Cancer, Springer; 2017. xvii 1024.
6. Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus
statement. HPB 2015;17:669-80. DOI PubMed PMC
7. Kubo S, Shinkawa H, Asaoka Y, et al. Liver cancer study group of Japan clinical practice guidelines for intrahepatic
cholangiocarcinoma. Liver Cancer 2022;11:290-314. DOI PubMed PMC
8. Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold
common disease process for carcinogenesis. Eur J Cancer 2010;46:1056-61. DOI
9. Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma:
etiological, clinicopathological, and molecular features. Mod Pathol 2014;27:1163-73. DOI PubMed
10. Wang XW, Thorgeirsson SS. The biological and clinical challenge of liver cancer heterogeneity. Hepat Oncol 2014;1:349-53. DOI
PubMed PMC
11. Shen X, Zhao H, Jin X, et al. Development and validation of a machine learning-based nomogram for prediction of intrahepatic
cholangiocarcinoma in patients with intrahepatic lithiasis. Hepatobiliary Surg Nutr 2021;10:749-65. DOI PubMed PMC
12. Bao F, Liu J, Chen H, Miao L, Xu Z, Zhang G. Diagnosis biomarkers of cholangiocarcinoma in human bile: an evidence-based study.
Cancers 2022;14:3921. DOI PubMed PMC
13. Liu XF, Tang K, Sui LL, Xu G. Cholangiocarcinoma: present status and molecular aspects of diagnosis. Oncol Res 2014;22:177-83.
DOI PubMed PMC
14. Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances.